Tyra Biosciences, Inc.
TYRA
$12.20
$0.504.27%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 35.45% | 39.05% | 38.43% | 25.92% | 34.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.45% | 29.34% | 30.34% | 44.37% | 61.75% |
| Operating Income | -27.45% | -29.34% | -30.34% | -44.37% | -61.75% |
| Income Before Tax | -30.86% | -27.82% | -25.09% | -41.46% | -59.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.86% | -27.82% | -25.09% | -41.46% | -59.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.86% | -27.82% | -25.09% | -41.46% | -59.97% |
| EBIT | -27.45% | -29.34% | -30.34% | -44.37% | -61.75% |
| EBITDA | -27.45% | -29.31% | -30.27% | -44.39% | -61.94% |
| EPS Basic | -5.63% | 3.00% | 6.72% | -15.51% | -41.56% |
| Normalized Basic EPS | -5.63% | 3.02% | 6.73% | -15.50% | -41.55% |
| EPS Diluted | -5.63% | 3.00% | 6.72% | -15.51% | -41.56% |
| Normalized Diluted EPS | -5.63% | 3.02% | 6.73% | -15.50% | -41.55% |
| Average Basic Shares Outstanding | 20.38% | 30.60% | 33.96% | 25.10% | 16.28% |
| Average Diluted Shares Outstanding | 20.38% | 30.60% | 33.96% | 25.10% | 16.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |